Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy | Zendy

Babafemi Taiwo | Zendy; R. M. Matining | Zendy; Lei Zheng | Zendy; M. M. Lederman | Zendy; C. R. Rinaldo | Zendy; Peter S. Kim | Zendy; B. I. Berzins | Zendy; Daniel R. Kuritzkes | Zendy; A. Jennings | Zendy; Joseph J. Eron | Zendy; C. C. Wilson | Zendy

Open Access

Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy

Author(s) -

Babafemi Taiwo,

R. M. Matining,

Lei Zheng,

M. M. Lederman,

C. R. Rinaldo,

Peter S. Kim,

B. I. Berzins,

Daniel R. Kuritzkes,

A. Jennings,

Joseph J. Eron,

C. C. Wilson

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt120

Subject(s) - raltegravir , darunavir , medicine , ritonavir , immunology , hazard ratio , cd38 , gastroenterology , regimen , proportional hazards model , viral load , antiretroviral therapy , human immunodeficiency virus (hiv) , biology , confidence interval , stem cell , cd34 , genetics

One of the goals of antiretroviral therapy (ART) is to attenuate HIV-induced systemic immune activation and inflammation. We determined the dynamics of biomarkers of immune activation, microbial translocation and inflammation during initial ART with a nucleos(t)ide-sparing regimen of darunavir/ritonavir plus raltegravir. We also evaluated associations between these biomarkers and the virological response to the regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research